Review of novel particulate antigen delivery systems with special focus on treatment of type I allergy

Journal of Controlled Release

Volumn 104, Issue 1, 2005, Pages 1-27

  Schöll, Isabella ^a   Boltz Nitulescu, George ^a   Jensen Jarolim, Erika ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Allergen delivery; Drug delivery; Microspheres; Novel carriers; Particles

Indexed keywords

ALLERGIES; AMINO ACIDS; DISEASES; DNA; IMMUNOLOGY; MOLECULAR BIOLOGY; POLYSACCHARIDES; PROTEINS;

ALLERGY TREATMENT; ANTIGEN DELIVERY SYSTEM; MICROPARTICLES; POLYACRYLICS;

ANTIGENS;

ACRYLIC ACID DERIVATIVE; ALGINIC ACID; ALLERGEN; ALUMINUM POTASSIUM SULFATE; AMINO ACID DERIVATIVE; ARCHAEOSOME; ASCORBYL PALMITATE; ASPASOME; CHITIN; CHITOSAN; COLLAGEN; CONJUVAC; CYTOKINE; DRUG CARRIER; EUDRAGIT; GAMMA INTERFERON; GELATIN; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; INTERLEUKIN 4; ISCOM; LIPID; LIPOSOME; MICROSPHERE; OVALBUMIN; POLYACRYLAMIDE; POLYMETHACRYLIC ACID DERIVATIVE; RAGWEED ANTIGEN; STARCH MICROSPHERE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY TITER; ANTIGEN PRESENTING CELL; ARCHAEBACTERIUM; BACTERIAL MEMBRANE; CELLULAR IMMUNITY; CLINICAL TRIAL; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; EDEMA; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; HOUSE DUST ALLERGY; HUMAN; HUMORAL IMMUNITY; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNIZATION; MACROPHAGE; MICROCAPSULE; NONHUMAN; PARTICLE SIZE; PARTICULATE MATTER; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SPLEEN CELL; TH1 CELL; TH2 CELL; URTICARIA;

EID: 18144388287     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.12.020     Document Type: Review

References (234)

1. D. Vercelli Molecular regulation of the IgE immune response Clin. Exp. Allergy 25 Suppl. 2 1995 43 45
2. R.C. Aalberse, R. van der Gaag, and J. van Leeuwen Serologic aspects of IgG4 antibodies: I. Prolonged immunization results in an IgG4-restricted response J. Immunol. 130 1983 722 726
3. J.A. Woodfolk, and T.A. Platts-Mills The immune response to intrinsic and extrinsic allergens: determinants of allergic disease Int. Arch. Allergy Immunol. 129 2002 277 285
4. W.C. Hanly, J.E. Artwohl, and B.T. Bennett Review of polyclonal antibody production procedures in mammals and poultry ILAR J. 37 1995 93 118
5. M. Singh, and D. O'Hagan Advances in vaccine adjuvants Nat. Biotechnol. 17 1999 1075 1081
6. J.M. Brewer, M. Conacher, C.A. Hunter, M. Mohrs, F. Brombacher, and J. Alexander Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling J. Immunol. 163 1999 6448 6454
7. T.R. Mosmann, and R.L. Coffman TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties Annu. Rev. Immunol. 7 1989 145 173
8. M. Vogelbruch, B. Nuss, M. Korner, A. Kapp, P. Kiehl, and W. Bohm Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations Allergy 55 2000 883 887
9. G. Gastaminza, J. Algorta, M. Audicana, M. Etxenagusia, E. Fernandez, and D. Munoz Systemic reactions to immunotherapy: influence of composition and manufacturer Clin. Exp. Allergy 33 2003 470 474
10. D.T. O'Hagan, and N.M. Valiante Recent advances in the discovery and delivery of vaccine adjuvants Nat. Rev. Drug Discov. 2 2003 727 735
11. K.M. Lima, and J.M. Rodrigues Jr. Poly-dl-lactide-co-glycolide microspheres as a controlled release antigen delivery system Braz. J. Med. Biol. Res. 32 1999 171 180
12. P.A. Drewes, A.O. Kamp, and J.W. Winkelman Radioimmunoassay of polyacrylamide Experientia 34 1978 316 319
13. P. Edman, and I. Sjoholm Acrylic microspheres in vivo V: immunological properties of immobilized asparaginase in microparticles J. Pharm. Sci. 71 1982 576 580
14. D.T. O'Hagan, K. Palin, S.S. Davis, P. Artursson, and I. Sjoholm Microparticles as potentially orally active immunological adjuvants Vaccine 7 1989 421 424
15. K.S. Barone, M.R. Reilly, M.P. Flanagan, and J.G. Michael Abrogation of oral tolerance by feeding encapsulated antigen Cell. Immunol. 199 2000 65 72
16. W.N. Haining, D.G. Anderson, S.R. Little, M.S. von Berwelt-Baildon, A.A. Cardoso, P. Alves, K. Kosmatopoulos, L.M. Nadler, R. Langer, and D.S. Kohane pH-triggered microparticles for peptide vaccination J. Immunol. 173 2004 2578 2585
17. M.A. Van Deusen, B.L. Angelini, K.M. Cordoro, B.A. Seiler, L. Wood, and D.P. Skoner Efficacy and safety of oral immunotherapy with short ragweed extract Ann. Allergy Asthma Immunol. 78 1997 573 580
18. A. Litwin, M. Flanagan, G. Entis, G. Gottschlich, R. Esch, P. Gartside, and J.G. Michael Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study J. Allergy Clin. Immunol. 100 1997 30 38
19. A. Litwin, M. Flanagan, G. Entis, G. Gottschlich, R. Esch, P. Gartside, and J.G. Michael Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy Ann. Allergy Asthma Immunol. 77 1996 132 138
20. A.W. Wheeler, D.C. Henderson, L.J. Youlten, J. Al II, B.E. Hickman, I.H. Taylor, and D.M. Moran Immunogenicity in guinea pigs and tolerance in grass pollen-sensitive volunteers of enteric-coated grass pollen allergens Int. Arch. Allergy Appl. Immunol. 83 1987 354 358
21. K. Vogel, J. Kantor, L. Wood, R. Rivera, and J. Schlom Oral immunization with enterocoated microbeads induces antigen-specific cytolytic T-cell responses Cell. Immunol. 190 1998 61 67
22. L. Degling, and P. Stjarnkvist Biodegradable microspheres: XVIII. The adjuvant effect of polyacryl starch microparticles with conjugated human serum albumin Vaccine 13 1995 629 636
23. C. Sturesson, and L. Degling Wikingsson Comparison of poly(acryl starch) and poly(lactide-co-glycolide) microspheres as drug delivery system for a rotavirus vaccine J. Control. Release 68 2000 441 450
24. L. Wikingsson, and I. Sjoholm Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice Vaccine 20 2002 3355 3363
25. L. Strindelius, L. Degling Wikingsson, and I. Sjoholm Extracellular antigens from Salmonella enteritidis induce effective immune response in mice after oral vaccination Infect. Immun. 70 2002 1434 1442
26. T. Laakso, P. Edman, and U. Brunk Biodegradable microspheres: VII. Alterations in mouse liver morphology after intravenous administration of polyacryl starch microparticles with different biodegradability J. Pharm. Sci. 77 1988 138 144
27. W.A. Taylor, D. Sheldon, and J.W. Spicer Adjuvant and suppressive effects of Grass Conjuvac and other alginate conjugates on IgG and IgE antibody responses in mice Immunology 44 1981 41 50
28. W.A. Taylor, and D.H. Francis Grass conjuvac: I. Immunogenicity in rabbits, guinea pigs and rats Int. Arch. Allergy Appl. Immunol. 72 1983 79 83
29. W.A. Taylor, A.K. Cane, and M.D. Hammond Grass Conjuvac: II. Pro-inflammatory activity and potential for inducing hypersensitivity Int. Arch. Allergy Appl. Immunol. 73 1984 38 41
30. C. Ortolani, E.A. Pastorello, C. Incorvaia, M. Ispano, L. Farioli, C. Zara, V. Pravettoni, and C. Zanussi A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever Allergy 49 1994 13 21
31. O.J. Corrado, E. Pastorello, S. Ollier, L. Cresswell, C. Zanussi, C. Ortolani, A. Incorvaia, A. Fugazza, J.R. Lovely, and R.I. Harris A double-blind study of hyposensitization with an alginate conjugated extract of D. pteronyssinus (Conjuvac) in patients with perennial rhinitis: 1. Clinical aspects Allergy 44 1989 108 115
32. R.D. Grembiale, L. Camporota, S. Naty, C.M. Tranfa, R. Djukanovic, and S.A. Marsico Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness Am. J. Respir. Crit. Care Med. 162 2000 2048 2052
33. N.H. Cho, S.Y. Seong, K.H. Chun, Y.H. Kim, I.C. Kwon, B.Y. Ahn, and S.Y. Jeong Novel mucosal immunization with polysaccharide-protein conjugates entrapped in alginate microspheres J. Control. Release 53 1998 215 224
34. S.Y. Seong, N.H. Cho, I.C. Kwon, and S.Y. Jeong Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae Infect. Immun. 67 1999 3587 3592
35. S.K. Mittal, N. Aggarwal, G. Sailaja, A. van Olphen, H. HogenEsch, A. North, J. Hays, and S. Moffatt Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response Vaccine 19 2000 253 263
36. M. Junghans, J. Kreuter, and A. Zimmer Antisense delivery using protamine-oligonucleotide particles Nucleic Acids Res. 28 2000 E45
37. M. Junghans, J. Kreuter, and A. Zimmer Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles Biochim. Biophys. Acta 1544 2001 177 188
38. R. Porsche, and Z.R. Brenner Allergy to protamine sulfate Heart Lung 28 1999 418 428
39. A. Constancis, R. Meyrueix, N. Bryson, S. Huille, J.M. Grosselin, T. Gulik-Krzywicki, and G. Soula Macromolecular colloids of diblock poly(amino acids) that bind insulin J. Colloid Interface Sci. 217 1999 357 368
40. J.H. Butterfield, G.J. Gleich, J.W. Yunginger, E.M. Zimmermann, and C.E. Reed Immunotherapy with short ragweed fraction A:d-glutamic acid: d-lysine polymer in ragweed hay fever J. Allergy Clin. Immunol. 67 1981 272 278
41. D. Gopinath, D. Ravi, B.R. Rao, S.S. Apte, and D. Rambhau l-O-Alkylglycerol vesicles (Algosomes): their formation and characterization Int. J. Pharm. 246 2002 187 197
42. D. Gopinath, D. Ravi, B.R. Rao, S.S. Apte, D. Renuka, and D. Rambhau Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and applications Int. J. Pharm. 271 2004 95 113
43. A. Witte, G. Wanner, U. Blasi, G. Halfmann, M. Szostak, and W. Lubitz Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E J. Bacteriol. 172 1990 4109 4114
44. V. Huter, M.P. Szostak, J. Gampfer, S. Prethaler, G. Wanner, F. Gabor, and W. Lubitz Bacterial ghosts as drug carrier and targeting vehicles J. Control. Release 61 1999 51 63
45. S. Paukner, G. Kohl, K. Jalava, and W. Lubitz Sealed bacterial ghosts-novel targeting vehicles for advanced drug delivery of water-soluble substances J. Drug Target 11 2003 151 161
46. W. Lubitz Bacterial ghosts as carrier and targeting systems Expert Opin. Biol. Ther. 1 2001 765 771
47. S. Paukner, G. Kohl, and W. Lubitz Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells J. Control. Release 94 2004 63 74
48. A.G. Haslberger, G. Kohl, D. Felnerova, U.B. Mayr, S. Furst-Ladani, and W. Lubitz Activation, stimulation and uptake of bacterial ghosts in antigen presenting cells J. Biotechnol. 83 2000 57 66
49. F.O. Eko, W. Lubitz, L. McMillan, K. Ramey, T.T. Moore, G.A. Ananaba, D. Lyn, C.M. Black, and J.U. Igietseme Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis Vaccine 21 2003 1694 1703
50. T. Ebensen, S. Paukner, C. Link, P. Kudela, C. de Domenico, W. Lubitz, and C.A. Guzman Bacterial ghosts are an efficient delivery system for DNA vaccines J. Immunol. 172 2004 6858 6865
51. F.O. Eko, A. Witte, V. Huter, B. Kuen, S. Furst-Ladani, A. Haslberger, A. Katinger, A. Hensel, M.P. Szostak, S. Resch, H. Mader, P. Raza, E. Brand, J. Marchart, W. Jechlinger, W. Haidinger, and W. Lubitz New strategies for combination vaccines based on the extended recombinant bacterial ghost system Vaccine 17 1999 1643 1649
52. I.M. van der Lubben, J.C. Verhoef, G. Borchard, and H.E. Junginger Chitosan and its derivatives in mucosal drug and vaccine delivery Eur. J. Pharm. Sci. 14 2001 201 207
53. R. Bourbouze, F. Raffi, G. Dameron, H. Hali-Miraftab, F. Loko, and J.L. Vilde N-acetyl-beta-d-glucosaminidase (NAG) isoenzymes release from human monocyte-derived macrophages in response to zymosan and human recombinant interferon-gamma Clin. Chim. Acta 199 1991 185 194
54. P.G. Seferian, and M.L. Martinez Immune stimulating activity of two new chitosan containing adjuvant formulations Vaccine 19 2000 661 668
55. R. Muzzarelli, G. Biagini, A. Pugnaloni, O. Filippini, V. Baldassarre, C. Castaldini, and C. Rizzoli Reconstruction of parodontal tissue with chitosan Biomaterials 10 1989 598 603
56. G. Peluso, O. Petillo, M. Ranieri, M. Santin, L. Ambrosio, D. Calabro, B. Avallone, and G. Balsamo Chitosan-mediated stimulation of macrophage function Biomaterials 15 1994 1215 1220
57. C. Qin, Y. Du, L. Xiao, Z. Li, and X. Gao Enzymic preparation of water-soluble chitosan and their antitumor activity Int. J. Biol. Macromol. 31 2002 111 117
58. K. Nishimura, S. Nishimura, N. Nishi, I. Saiki, S. Tokura, and I. Azuma Immunological activity of chitin and its derivatives Vaccine 2 1984 93 99
59. J. Iida, T. Une, C. Ishihara, K. Nishimura, S. Tokura, N. Mizukoshi, and I. Azuma Stimulation of non-specific host resistance against Sendai virus and Escherichia coli infections by chitin derivatives in mice Vaccine 5 1987 270 274
60. D.Y. Lee, I.S. Choi, J.H. Han, and H.S. Yoo Chitosan and d-glucosamine induce expression of Th1 cytokine genes in porcine spleen cells J. Vet. Med. Sci. 64 2002 645 648
61. C. Porporatto, I.D. Bianco, A.M. Cabanillas, and S.G. Correa Early events associated to the oral co-administration of type II collagen and chitosan: induction of anti-inflammatory cytokines Int. Immunol. 16 2004 433 441
62. Y. Shibata, I. Honda, J.P. Justice, M.R. Van Scott, R.M. Nakamura, and Q.N. Myrvik Th1 adjuvant N-acetyl-d-glucosamine polymer up-regulates Th1 immunity but down-regulates Th2 immunity against a mycobacterial protein (MPB-59) in interleukin-10-knockout and wild-type mice Infect. Immun. 69 2001 6123 6130
63. K. Nishimura, S. Nishimura, N. Nishi, F. Numata, Y. Tone, S. Tokura, and I. Azuma Adjuvant activity of chitin derivatives in mice and guinea-pigs Vaccine 3 1985 379 384
64. N.G. Schipper, K.M. Varum, P. Stenberg, G. Ocklind, H. Lennernas, and P. Artursson Chitosans as absorption enhancers of poorly absorbable drugs: 3. Influence of mucus on absorption enhancement Eur J. Pharm. Sci. 8 1999 335 343
65. N.G. Schipper, S. Olsson, J.A. Hoogstraate, A.G. deBoer, K.M. Varum, and P. Artursson Chitosans as absorption enhancers for poorly absorbable drugs: 2. Mechanism of absorption enhancement Pharm. Res. 14 1997 923 929
66. N.G. Schipper, K.M. Varum, and P. Artursson Chitosans as absorption enhancers for poorly absorbable drugs: 1. Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells Pharm. Res. 13 1996 1686 1692
67. I.M. van der Lubben, J.C. Verhoef, A.C. van Aelst, G. Borchard, and H.E. Junginger Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches Biomaterials 22 2001 687 694
68. I.M. van der Lubben, F.A. van Opdorp, M.R. Hengeveld, J.J. Onderwater, H.K. Koerten, J.C. Verhoef, G. Borchard, and H.E. Junginger Transport of chitosan microparticles for mucosal vaccine delivery in a human intestinal M-cell model J. Drug Target 10 2002 449 456
69. A. Bernkop-Schnurch, D. Guggi, and Y. Pinter Thiolated chitosans: development and in vitro evaluation of a mucoadhesive, permeation enhancing oral drug delivery system J. Control. Release 94 2004 177 186
70. A. Bernkop-Schnurch, C.E. Kast, and D. Guggi Permeation enhancing polymers in oral delivery of hydrophilic macromolecules: thiomer/GSH systems J. Control. Release 93 2003 95 103
71. A. Bernkop-Schnurch, M. Hornof, and D. Guggi Thiolated chitosans Eur. J. Pharm. Biopharm. 57 2004 9 17
72. A. Schaffner, H. Douglas, and A. Braude Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes J. Clin. Invest. 69 1982 617 631
73. Y. Shibata, W.J. Metzger, and Q.N. Myrvik Chitin particle-induced cell-mediated immunity is inhibited by soluble mannan: mannose receptor-mediated phagocytosis initiates IL-12 production J. Immunol. 159 1997 2462 2467
74. Y. Shibata, L.A. Foster, J.F. Bradfield, and Q.N. Myrvik Oral administration of chitin down-regulates serum IgE levels and lung eosinophilia in the allergic mouse J. Immunol. 164 2000 1314 1321
75. J. Pappo, and T.H. Ermak Uptake and translocation of fluorescent latex particles by rabbit Peyer's patch follicle epithelium: a quantitative model for M cell uptake Clin. Exp. Immunol. 76 1989 144 148
76. T.H. Ermak, E.P. Dougherty, H.R. Bhagat, Z. Kabok, and J. Pappo Uptake and transport of copolymer biodegradable microspheres by rabbit Peyer's patch M cells Cell Tissue Res. 279 1995 433 436
77. M. Kumar, X. Kong, A.K. Behera, G.R. Hellermann, R.F. Lockey, and S.S. Mohapatra Chitosan IFN-gamma-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma Genet. Vaccines Ther. 1 2003 3
78. K. Roy, H.Q. Mao, S.K. Huang, and K.W. Leong Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy Nat. Med. 5 1999 387 391
79. J.L. Chew, C.B. Wolfowicz, H.Q. Mao, K.W. Leong, and K.Y. Chua Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice Vaccine 21 2003 2720 2729
80. P. Strong, H. Clark, and K. Reid Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy Clin. Exp. Allergy 32 2002 1794 1800
81. G. Hall, L. Lund, J.R. Lamb, and E.R. Jarman Kinetics and mode of peptide delivery via the respiratory mucosa determine the outcome of activation vs. TH2 immunity in allergic inflammation of the airways J. Allergy Clin. Immunol. 110 2002 883 890
82. A. Sano, M. Maeda, S. Nagahara, T. Ochiya, K. Honma, H. Itoh, T. Miyata, and K. Fujioka Atelocollagen for protein and gene delivery Adv. Drug Deliv. Rev. 55 2003 1651 1677
83. S. Lofthouse, S. Nagahara, B. Sedgmen, G. Barcham, M. Brandon, and A. Sano The application of biodegradable collagen minipellets as vaccine delivery vehicles in mice and sheep Vaccine 19 2001 4318 4327
84. A.W. Klein Skin filling. Collagen and other injectables of the skin Dermatol. Clin. 19 2001 491 508
85. C.J. Doillon, M.G. Dunn, R.A. Berg, and F.H. Silver Collagen deposition during wound repair Scanning Electron Microsc. 1985 897 903
86. K.H. Stenzel, T. Miyata, and A.L. Rubin Collagen as a biomaterial Annu. Rev. Biophys. Bioeng. 3 1974 231 253
87. M. Maeda, K. Kadota, M. Kajihara, A. Sano, and K. Fujioka Sustained release of human growth hormone (hGH) from collagen film and evaluation of effect on wound healing in db/db mice J. Control. Release 77 2001 261 272
88. M. Maeda, S. Tani, A. Sano, and K. Fujioka Microstructure and release characteristics of the minipellet, a collagen-based drug delivery system for controlled release of protein drugs J. Control. Release 62 1999 313 324
89. A. Sano, T. Hojo, M. Maeda, and K. Fujioka Protein release from collagen matrices Adv. Drug Deliv. Rev. 31 1998 247 266
90. M. Higaki, Y. Azechi, T. Takase, R. Igarashi, S. Nagahara, A. Sano, K. Fujioka, N. Nakagawa, C. Aizawa, and Y. Mizushima Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid Vaccine 19 2001 3091 3096
91. K. Honma, T. Ochiya, S. Nagahara, A. Sano, H. Yamamoto, K. Hirai, Y. Aso, and M. Terada Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions Biochem. Biophys. Res. Commun. 289 2001 1075 1081
92. T. Ochiya, Y. Takahama, S. Nagahara, Y. Sumita, A. Hisada, H. Itoh, Y. Nagai, and M. Terada New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material: the Minipellet Nat. Med. 5 1999 707 710
93. A. Asghar, and R.L. Henrickson Chemical, biochemical, functional, and nutritional characteristics of collagen in food systems Adv. Food Res. 28 1982 231 372
94. C.A. Farrugia, and M.J. Groves Gelatin behaviour in dilute aqueous solution: designing a nanoparticulate formulation J. Pharm. Pharmacol. 51 1999 643 649
95. D. Olsen, C. Yang, M. Bodo, R. Chang, S. Leigh, J. Baez, D. Carmichael, M. Perala, E.R. Hamalainen, M. Jarvinen, and J. Polarek Recombinant collagen and gelatin for drug delivery Adv. Drug Deliv. Rev. 55 2003 1547 1567
96. H.C. Liang, W.H. Chang, K.J. Lin, and H.W. Sung Genipin-cross-linked gelatin microspheres as a drug carrier for intramuscular administration: in vitro and in vivo studies J. Biomed. Mater. Res. 65A 2003 271 282
97. R. Nakaoka, Y. Tabata, and Y. Ikada Potentiality of gelatin microsphere as immunological adjuvant Vaccine 13 1995 653 661
98. K. Iwanaga, T. Yabuta, M. Kakemi, K. Morimoto, Y. Tabata, and Y. Ikada Usefulness of microspheres composed of gelatin with various cross-linking density J. Microencapsul. 20 2003 767 776
99. M. Preda, and S.E. Leucuta Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization J. Microencapsul. 20 2003 777 789
100. K. Mladenovska, E.I. Janevik, M.D. Glavas, E.F. Kumbaradzi, and K. Goracinova Biodistribution studies of BSA loaded gelatin microspheres after peroral application Int. J. Pharm. 242 2002 251 253
101. J.K. Li, N. Wang, and X.S. Wu A novel biodegradable system based on gelatin nanoparticles and poly(lactic-co-glycolic acid) microspheres for protein and peptide drug delivery J. Pharm. Sci. 86 1997 891 895
102. J.K. Li, N. Wang, and X.S. Wu Gelatin nanoencapsulation of protein/peptide drugs using an emulsifier-free emulsion method J. Microencapsul. 15 1998 163 172
103. K. Mladenovska, E.I. Janevik, M.D. Glavas, E.F. Kumbaradzi, and K. Goracinova Biodistribution of 131I-BSA loaded gelatin microspheres after peroral application to BALB/c mice-particle size study Acta Pharm. 53 2003 187 197
104. V. Pool, M.M. Braun, J.M. Kelso, G. Mootrey, R.T. Chen, J.W. Yunginger, R.M. Jacobson, and P.M. Gargiullo Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States Pediatrics 110 2002 e71
105. B. Morein, B. Sundquist, S. Hoglund, K. Dalsgaard, and A. Osterhaus Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses Nature 308 1984 457 460
106. G.F. Kersten, A. Spiekstra, E.C. Beuvery, and D.J. Crommelin On the structure of immune-stimulating saponin-lipid complexes (iscoms) Biochim. Biophys. Acta 1062 1991 165 171
107. J.C. Cox, A. Sjolander, and I.G. Barr ISCOMs and other saponin based adjuvants Adv. Drug Deliv. Rev. 32 1998 247 271
108. G. Reid Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid Vaccine 10 1992 597 602
109. K.J. Maloy, A.M. Donachie, and A.M. Mowat Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS Eur J. Immunol. 25 1995 2835 2841
110. A.M. Mowat, K.J. Maloy, and A.M. Donachie Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens Immunology 80 1993 527 534
111. R.E. Smith, A.M. Donachie, F.H. McLaren, and A.M. Mowat Preservation of mucosal and systemic adjuvant properties of ISCOMS in the absence of functional interleukin-4 or interferon-gamma Immunology 93 1998 556 562
112. S. Behboudi, B. Morein, and M. Villacres-Eriksson In vitro activation of antigen-presenting cells (APC) by defined composition of Quillaja saponaria Molina triterpenoids Clin. Exp. Immunol. 105 1996 26 30
113. M. Bergstrom-Mollaoglu, K. Lovgren, L. Akerblom, C. Fossum, and B. Morein Antigen-specific increases in the number of splenocytes expressing MHC class II molecules following restimulation with antigen in various physical forms Scand. J. Immunol. 36 1992 565 574
114. E. Dotsika, E. Karagouni, B. Sundquist, B. Morein, A. Morgan, and M. Villacres-Eriksson Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms Scand J. Immunol. 45 1997 261 268
115. A. Sjolander, B. van't Land, and K. Lovgren Bengtsson Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses Cell. Immunol. 177 1997 69 76
116. M. Villacres-Eriksson, S. Behboudi, A.J. Morgan, G. Trinchieri, and B. Morein Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response Cytokine 9 1997 73 82
117. H. Takahashi, T. Takeshita, B. Morein, S. Putney, R.N. Germain, and J.A. Berzofsky Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs Nature 344 1990 873 875
118. J.A. Mumford, D. Jessett, U. Dunleavy, J. Wood, D. Hannant, B. Sundquist, and R.F. Cook Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines Vaccine 12 1994 857 863
119. G.F. Kersten, and D.J. Crommelin Liposomes and ISCOMs Vaccine 21 2003 915 920
120. L. Krishnan, C.J. Dicaire, G.B. Patel, and G.D. Sprott Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: comparison to conventional liposomes and alum Infect. Immun. 68 2000 54 63
121. G.D. Sprott, G.B. Patel, and L. Krishnan Archaeobacterial ether lipid liposomes as vaccine adjuvants Methods Enzymol. 373 2003 155 172
122. C.G. Choquet, G.B. Patel, T.J. Beveridge, and G.D. Sprott Stability of pressure-extruded liposomes made from archaeobacterial ether lipids Appl. Microbiol. Biotechnol. 42 1994 375 384
123. G.B. Patel, and G.D. Sprott Archaeobacterial ether lipid liposomes (archaeosomes) as novel vaccine and drug delivery systems Crit. Rev. Biotechnol. 19 1999 317 357
124. A. Omri, B.J. Agnew, and G.B. Patel Short-term repeated-dose toxicity profile of archaeosomes administered to mice via intravenous and oral routes Int. J. Toxicol. 22 2003 9 23
125. G.B. Patel, B.J. Agnew, L. Deschatelets, L.P. Fleming, and G.D. Sprott In vitro assessment of archaeosome stability for developing oral delivery systems Int. J. Pharm. 194 2000 39 49
126. L. Krishnan, S. Sad, G.B. Patel, and G.D. Sprott Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge Cancer Res. 63 2003 2526 2534
127. L. Krishnan, S. Sad, G.B. Patel, and G.D. Sprott Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help J. Immunol. 165 2000 5177 5185
128. S. Gould-Fogerite, M.T. Kheiri, F. Zhang, Z. Wang, A.J. Scolpino, E. Feketeova, M. Canki, and R.J. Mannino Targeting immune response induction with cochleate and liposome-based vaccines Adv. Drug Deliv. Rev. 32 1998 273 287
129. S. Gould-Fogerite, Y. Edghill-Smith, M. Kheiri, Z. Wang, K. Das, E. Feketeova, M. Canki, and R.J. Mannino Lipid matrix-based subunit vaccines: a structure-function approach to oral and parenteral immunization AIDS Res. Hum. Retrovir. 10 Suppl. 2 1994 S99 S103
130. R.J. Mannino, and S. Gould-Fogerite Lipid matrix-based vaccines for mucosal and systemic immunization Pharm. Biotechnol. 6 1995 363 387
131. S. Gould-Fogerite, J. Oleske, R.J. Mannino, A.J. Scolpino, B. Holland, P. Ferrara, D. D'Orlando, P. Palumbo, R. Chakraborty, and T. Denny Clinical and laboratory safety and initial efficacy studies with an autigenous HIV cellular/viral therapeutic vaccine utilizing a Sendai virus envelope derived adjuvant (SDE) J. AIDS Res. Human Retrovirol. 14s 1997 142
132. G.F. Kersten, and D.J. Crommelin Liposomes and ISCOMS as vaccine formulations Biochim. Biophys. Acta 1241 1995 117 138
133. R.N. Rowland, and J.F. Woodley The stability of liposomes in vitro to pH, bile salts and pancreatic lipase Biochim. Biophys. Acta 620 1980 400 409
134. I. Genin, G. Barratt, X.T. Tran, J. Delattre, and F. Puisieux Optimization and characterization of freeze-dried multilamellar liposomes incorporating different standardized allergen extracts Allergy 49 1994 645 652
135. S. Ouadahi, M. Paternostre, C. Andre, I. Genin, T.X. Thao, F. Puisieux, J.P. Devissaguet, and G. Barratt Liposomal formulations for oral immunotherapy: in-vitro stability in synthetic intestinal media and in-vivo efficacy in the mouse J. Drug Target 5 1998 365 378
136. S. Naito, A. Horino, M. Nakayama, Y. Nakano, T. Nagai, J. Mizuguchi, K. Komuro, and T. Uchida Ovalbumin-liposome conjugate induces IgG but not IgE antibody production Int. Arch. Allergy Immunol. 109 1996 223 228
137. Y. Nakano, M. Mori, S. Nishinohara, Y. Takita, S. Naito, A. Horino, H. Kato, M. Taneichi, Y. Ami, Y. Suzaki, K. Komuro, and T. Uchida Antigen-specific, IgE-selective unresponsiveness induced by antigen-liposome conjugates. Comparison of four different conjugation methods for the coupling of antigen to liposome Int. Arch. Allergy Immunol. 120 1999 199 208
138. N. Arora, and S.V. Gangal Allergens entrapped in liposomes reduce allergenicity and induce immunogenicity on repeated injections in mice Int. Arch. Allergy Appl. Immunol. 91 1990 22 29
139. N. Arora, and S.V. Gangal Liposomes as vehicle for allergen presentation in the immunotherapy of allergic diseases Allergy 46 1991 386 392
140. A. Basomba, A.I. Tabar, D.H. de Rojas, B.E. Garcia, R. Alamar, J.M. Olaguibel, J.M. del Prado, S. Martin, and P. Rico Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients J. Allergy Clin. Immunol. 109 2002 943 948
141. M.J. Alvarez, S. Echechipia, B. Garcia, A.I. Tabar, S. Martin, P. Rico, and J.M. Olaguibel Liposome-entrapped D. pteronyssinus vaccination in mild asthma patients: effect of 1-year double-blind, placebo-controlled trial on inflammation, bronchial hyperresponsiveness and immediate and late bronchial responses to the allergen Clin. Exp. Allergy 32 2002 1574 1582
142. J. Szebeni Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents Crit. Rev. Ther. Drug Carrier Syst. 18 2001 567 606
143. R.K. Gupta, C.L. Varanelli, P. Griffin, D.F. Wallach, and G.R. Siber Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens Vaccine 14 1996 219 225
144. J.M. Brewer, and J. Alexander Studies on the adjuvant activity of non-ionic surfactant vesicles: adjuvant-driven IgG2a production independent of MHC control Vaccine 12 1994 613 619
145. J.M. Brewer, and J. Alexander The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin Immunology 75 1992 570 575
146. C.O. Rentel, J.A. Bouwstra, B. Naisbett, and H.E. Junginger Niosomes as a novel peroral vaccine delivery system Int. J. Pharm. 186 1999 161 167
147. S.C. Chattaraj, and S.K. Das Physicochemical characterization of influenza viral vaccine loaded surfactant vesicles Drug Deliv. 10 2003 73 77
148. J.Y. Fang, C.T. Hong, W.T. Chiu, and Y.Y. Wang Effect of liposomes and niosomes on skin permeation of enoxacin Int. J. Pharm. 219 2001 61 72
149. T. Yoshioka, N. Skalko, M. Gursel, G. Gregoriadis, and A.T. Florence A non-ionic surfactant vesicle-in-water-in-oil (v/w/o) system: potential uses in drug and vaccine delivery J. Drug Target 2 1995 533 539
150. A. Paul, G. Cevc, and B.K. Bachhawat Transdermal immunization with large proteins by means of ultradeformable drug carriers Eur. J. Immunol. 25 1995 3521 3524
151. A. Paul, G. Cevc, and B.K. Bachhawat Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes Vaccine 16 1998 188 195
152. S.A. Walker, M.T. Kennedy, and J.A. Zasadzinski Encapsulation of bilayer vesicles by self-assembly Nature 387 1997 61 64
153. E.T. Kisak, B. Coldren, C.A. Evans, C. Boyer, and J.A. Zasadzinski The vesosome-a multicompartment drug delivery vehicle Curr. Med. Chem. 11 2004 199 219
154. R. Gluck Immunopotentiating reconstituted influenza virosomes (IRIVs) and other adjuvants for improved presentation of small antigens Vaccine 10 1992 915 919
155. P. Durrer, U. Gluck, C. Spyr, A.B. Lang, R. Zurbriggen, C. Herzog, and R. Gluck Mucosal antibody response induced with a nasal virosome-based influenza vaccine Vaccine 21 2003 4328 4334
156. R. Gluck Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs) Vaccine 17 1999 1782 1787
157. L. Bungener, A. Huckriede, J. Wilschut, and T. Daemen Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs Biosci. Rep. 22 2002 323 338
158. L. Bungener, J. Idema, W. ter Veer, A. Huckriede, T. Daemen, and J. Wilschut Virosomes in vaccine development: induction of cytotoxic T lymphocyte activity with virosome-encapsulated protein antigens J. Liposome Res. 12 2002 155 163
159. F. Ambrosch, G. Wiedermann, S. Jonas, B. Althaus, B. Finkel, R. Gluck, and C. Herzog Immunogenicity and protectivity of a new liposomal hepatitis A vaccine Vaccine 15 1997 1209 1213
160. A.G. Coombes, and M.C. Meikle Resorbable synthetic polymers as replacements for bone graft Biomaterials 15 1994 673 680
161. R.W. Postlethwait, and B.M. Smith A new synthetic absorbable suture Fed. Regist. 56 1991 47150 47151
162. O.L. Johnson, J.L. Cleland, H.J. Lee, M. Charnis, E. Duenas, W. Jaworowicz, D. Shepard, A. Shahzamani, A.J. Jones, and S.D. Putney A month-long effect from a single injection of microencapsulated human growth hormone J. Pharm. Sci. 85 1996 1346 1349
163. J.L. Cleland Solvent evaporation processes for the production of controlled release biodegradable microsphere formulations for therapeutics and vaccines Biotechnol. Prog. 14 1998 102 107
164. C. Witt, and T. Kissel Morphological characterization of microspheres, films and implants prepared from poly(lactide-co-glycolide) and ABA triblock copolymers: is the erosion controlled by degradation, swelling or diffusion? Eur. J. Pharm. Biopharm. 51 2001 171 181
165. K.M. Lima, and J.M. Rodrigues Jr. Poly-dl-lactide-co-glycolide microspheres as a controlled release antigen delivery system Infect. Immun. 69 2001 5305 5312
166. D.T. O'Hagan, H. Jeffery, M.J. Roberts, J.P. McGee, and S.S. Davis
167. A.K. Hilbert, U. Fritzsche, and T. Kissel Biodegradable microspheres containing influenza A vaccine: immune response in mice Vaccine 17 1999 1065 1073
168. D.H. Jones, B.W. McBride, H. Jeffery, D.T. O'Hagan, A. Robinson, and G.H. Farrar Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae Vaccine 13 1995 1741 1749
169. X.M. Lam, E.T. Duenas, and J.L. Cleland Encapsulation and stabilization of nerve growth factor into poly(lactic- co-glycolic) acid microspheres J. Control. Release 58 1999 223 232
170. A. Moore, P. McGuirk, S. Adams, W.C. Jones, J.P. McGee, D.T. O'Hagan, and K.H. Mills Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells Vaccine 14 1996 1523 1530
171. J.E. Rosas, R.M. Hernandez, A.R. Gascon, M. Igartua, F. Guzman, M.E. Patarroyo, and J.L. Pedraz Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66 Vaccine 19 2001 4445 4451
172. C. Sturesson, P. Artursson, R. Ghaderi, K. Johansen, A. Mirazimi, I. Uhnoo, L. Svensson, A.C. Albertsson, and J. Carlfors Encapsulation of rotavirus into poly(lactide-co-glycolide) microspheres J. Control. Release 59 1999 377 389
173. H.M. Vordermeier, A.G. Coombes, P. Jenkins, J.P. McGee, D.T. O'Hagan, S.S. Davis, and M. Singh Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles Vaccine 17 1999 1814 1819
174. S. Pecquet, E. Leo, R. Fritsche, A. Pfeifer, P. Couvreur, and E. Fattal Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres Ann. Pharm. Fr. 60 2002 44 49
175. K.J. Maloy, A.M. Donachie, D.T. O'Hagan, and A.M. Mowat Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles Immunology 81 1994 661 667
176. M. Singh, J. Kazzaz, J. Chesko, E. Soenawan, M. Ugozzoli, M. Giuliani, M. Pizza, R. Rappouli, and D.T. O'Hagan Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B J. Pharm. Sci. 93 2004 273 282
177. D.H. Jones, S. Corris, S. McDonald, J.C. Clegg, and G.H. Farrar Poly(dl-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration Vaccine 15 1997 814 817
178. H. Sah, and Y.W. Chien Prolonged immune response evoked by a single subcutaneous injection of microcapsules having a monophasic antigen release J. Physiol. Pharmacol. 50 1999 419 428
179. J.L. Cleland Single-administration vaccines: controlled-release technology to mimic repeated immunizations Pharm. Res. 16 1999 232 240
180. M. Igartua, R.M. Hernandez, A. Esquisabel, A.R. Gascon, M.B. Calvo, and J.L. Pedraz Enhanced immune response after subcutaneous and oral immunization with biodegradable PLGA microspheres J. Control. Release 56 1998 63 73
181. I.D. Spiers, J.E. Eyles, L.W. Baillie, E.D. Williamson, and H.O. Alpar Biodegradable microparticles with different release profiles: effect on the immune response after a single administration via intranasal and intramuscular routes J. Pharm. Pharmacol. 52 2000 1195 1201
182. J.H. Eldridge, J.A. Meulbroek, J.K. Staas, T.R. Tice, and R.M. Gilley Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response Adv. Exp. Med. Biol. 251 1989 191 202
183. J.H. Eldridge, R.M. Gilley, J.K. Staas, Z. Moldoveanu, J.A. Meulbroek, and T.R. Tice Biodegradable microspheres: vaccine delivery system for oral immunization Curr. Top. Microbiol. Immunol. 146 1989 59 66
184. J.H. Eldridge, J.K. Staas, J.A. Meulbroek, J.R. McGhee, T.R. Tice, and R.M. Gilley Biodegradable microspheres as a vaccine delivery system Vaccine 11 1993 965 969
185. J.L. Cleland, A. Lim, A. Daugherty, L. Barron, N. Desjardin, E.T. Duenas, D.J. Eastman, J.C. Vennari, T. Wrin, P. Berman, K.K. Murthy, and M.F. Powell Development of a single-shot subunit vaccine for HIV-1. 5. programmable in vivo autoboost and long lasting neutralizing response J. Pharm. Sci. 87 1998 1489 1495
186. M. Vajdy, and D.T. O'Hagan Microparticles for intranasal immunization Adv. Drug Deliv. Rev. 51 2001 127 141
187. P. Johansen, Y. Men, H.P. Merkle, and B. Gander Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination Eur. J. Pharm. Biopharm. 50 2000 129 146
188. E. Batanero, P. Barral, M. Villalba, and R. Rodriguez Biodegradable poly (dl-lactide glycolide) microparticles as a vehicle for allergen-specific vaccines: a study performed with Ole e 1, the main allergen of olive pollen J. Immunol. Methods 259 2002 87 94
189. E. Batanero, P. Barral, M. Villalba, and R. Rodriguez Encapsulation of Ole e 1 in biodegradable microparticles induces Th1 response in mice: a potential vaccine for allergy J. Control. Release 92 2003 395 398
190. M. Igartua, R.M. Hernandez, I. Gutierro, A.R. Gascon, and J.L. Pedraz Preliminary assessment of the immune response to Olea europaea pollen extracts encapsulated into PLGA microspheres Pharm. Dev. Technol. 6 2001 621 627
191. V. Guerin, M. Dubarryr, D. Robic, F. Brachet, M. Rautureau, C. Andre, R. Bourbouze, and D. Tome Microsphere entrapped bee-venom phospholipase A2 retains specific IgE binding capacity: a possible use for oral specific immunotherapy J. Microencapsul. 19 2002 761 765
192. S. Sharif, A.W. Wheeler, and D.T. O'Hagan C.R. Society Investigation of the Strucutral and Immunologic Integrity of an Allergen Entrapped in Poly(Lactide-Co-Glycolide) Microparticles 1994 Deerfield Nice, France 292 295
193. I. Schöll, A. Weissenböck, E. Förster-Waldl, E. Untersmayr, F. Walter, M. Willheim, G. Boltz-Nitulescu, O. Scheiner, F. Gabor, and E. Jensen-Jarolim Allergen-loaded biodegradable poly(dl-lactic-co-glycolic) acid nanoparticles down-regulate an ongoing Th2 response in the BALB/c mouse model Clin. Exp. Allergy 34 2004 315 321
194. F. Walter, I. Schöll, E. Untersmayr, A. Ellinger, G. Boltz-Nitulescu, O. Scheiner, F. Gabor, and E. Jensen-Jarolim Functionalisation of allergen-loaded microspheres with wheat germ agglutinin for targeting enterocytes Biochem. Biophys. Res. Commun. 315 2004 281 287
195. F. Walter, I. Schöll, E. Untersmayr, A. Ellinger, G. Boltz-Nitulescu, O. Scheiner, G. Gazzanelli, E. Jensen-Jarolim, Mucosal targeting of allergen-loaded microspheres by Aleuria aurantia lectin, Vaccine (in press).
196. F. Roth-Walter, I. Schöll, E. Untersmayr, R. Fuchs, G. Boltz-Nitulescu, O. Scheiner, G. Gazzanelli, and E. Jensen-Jarolim M-cell targeting with Aleuria aurantia lectin as a novel approach for oral allergen immunotherapy J. Allergy Clin. Immunol. 114 2004 1362 1368
197. I. Schöll, C. Gusenbauer, F. Gabor, G. Boltz-Nitulescu, O. Scheiner, and E. Jensen-Jarolim J. Bienenstock J. Ring A.G. Togias Biodegradable Nanospheres as Allergen Delivery-System in Immunizations of Balb/c Mice 2004 Hogrefe&Huber Cambridge, MA 324 326
198. G.H. Lowell, L.F. Smith, R.C. Seid, and W.D. Zollinger Peptides bound to proteosomes via hydrophobic feet become highly immunogenic without adjuvants J. Exp. Med. 167 1988 658 663
199. C.L. Ruegg, R.I. Jaffe, B. Koster, J.C. Sadoff, W.D. Zollinger, G.H. Lowell, and M. Strand Preparation of proteosome-based vaccines. Correlation of immunogenicity with physical characteristics J. Immunol. Methods 135 1990 101 109
200. T. Jones, F. Allard, S.L. Cyr, S.P. Tran, M. Plante, J. Gauthier, N. Bellerose, G.H. Lowell, and D.S. Burt A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity Vaccine 21 2003 3706 3712
201. R. Levi, E. Aboud-Pirak, C. Leclerc, G.H. Lowell, and R. Arnon Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes Vaccine 13 1995 1353 1359
202. P.O. Livingston, M.J. Calves, F. Helling, W.D. Zollinger, M.S. Blake, and G.H. Lowell GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3 Vaccine 11 1993 1199 1204
203. H. Gronlund, S. Vrtala, U. Wiedermann, G. Dekan, D. Kraft, R. Valenta, and M. Van Hage-Hamsten Carbohydrate-based particles: a new adjuvant for allergen-specific immunotherapy Immunology 107 2002 523 529
204. P. Pumpens, G.P. Borisova, R.A. Crowther, and E. Grens Hepatitis B virus core particles as epitope carriers Intervirology 38 1995 63 74
205. T. Storni, F. Lechner, I. Erdmann, T. Bachi, A. Jegerlehner, T. Dumrese, T.M. Kundig, C. Ruedl, and M.F. Bachmann Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles J. Immunol. 168 2002 2880 2886
206. C. Ruedl, T. Storni, F. Lechner, T. Bachi, and M.F. Bachmann Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP Eur. J. Immunol. 32 2002 818 825
207. T. Storni, C. Ruedl, K. Schwarz, R.A. Schwendener, W.A. Renner, and M.F. Bachmann Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects J. Immunol. 172 2004 1777 1785
208. A. Jegerlehner, A. Tissot, F. Lechner, P. Sebbel, I. Erdmann, T. Kundig, T. Bachi, T. Storni, G. Jennings, P. Pumpens, W.A. Renner, and M.F. Bachmann A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses Vaccine 20 2002 3104 3112
209. F. Lechner, A. Jegerlehner, A.C. Tissot, P. Maurer, P. Sebbel, W.A. Renner, G.T. Jennings, and M.F. Bachmann Virus-like particles as a modular system for novel vaccines Intervirology 45 2002 212 217
210. A.T. Glenny, C.G. Pope, H. Waddington, and U. Wallace The antigenic value of toxoid precipitated by potassium alum J. Pathol. Bacteriol. 29 1926 38 39
211. A.R. Zoss, C.A. Koch, and R.S. Hirose Alum-ragweed precipitate: preparation and clinical investigation; preliminary report J. Allergy 8 1937 329
212. R. Lindmark, E. Larsson, K. Nilsson, and J. Sjoquist Immobilization of proteins by entrapment in polyacrylamide microbeads J. Immunol. Methods 49 1982 159 177
213. J.W. McGinity, and C.S. Mehta Preparation and evaluation of a sustained morphine delivery system in rats Pharmacol. Biochem. Behav. 9 1978 705 708
214. N.G. Georgakis, A. Gerardi, C. Popovits, and E.B. Brown The use of alginate adjuvant as a vehicle in the treatment of ragweed pollinosis Ann. Allergy 25 1967 439 444
215. W.C. Shen, and H.J. Ryser Poly(l-lysine) has different membrane transport and drug-carrier properties when complexed with heparin Proc. Natl. Acad. Sci. U. S. A. 78 1981 7589 7593
216. G.D. Sprott, D.L. Tolson, and G.B. Patel Archaeosomes as novel antigen delivery systems FEMS Microbiol. Lett. 154 1997 17 22
217. J.M. Gallo, and E.E. Hassan Receptor-mediated magnetic carriers: basis for targeting Pharm. Res. 5 1988 300 304
218. S. Gould-Fogerite, J.E. Mazurkiewicz, K. Raska Jr., K. Voelkerding, J.M. Lehman, and R.J. Mannino Chimerasome-mediated gene transfer in vitro and in vivo Gene 84 1989 429 438
219. A.L. Rubin, K.H. Stenzel, T. Miyata, M.J. White, and M. Dunn Collagen as a vehicle for drug delivery. Preliminary report J. Clin. Pharmacol. 13 1973 309 312
220. M. Hashida, Y. Takahashi, S. Muranishi, and H. Sezaki An application of water-in-oil and gelatin-microsphere-in-oil emulsions to specific delivery of anticancer agent into stomach lymphatics J. Pharmacokinet. Biopharm. 5 1977 241 255
221. B. Bjorksten, C. Moller, U. Broberger, S. Ahlstedt, S. Dreborg, S.G. Johansson, P. Juto, and A. Lanner Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract Allergy 41 1986 290 295
222. Y.E. Rahman, and B.J. Wright Liposomes containing chelating agents. Cellular penetration and a possible mechanism of metal removal J. Cell Biol. 65 1975 112 122
223. V.N. Fedoseeva, and A.V. Barysheva Properties of liposomal allergens of Neisseria perflava Biull. Eksp. Biol. Med. 94 1982 87 90
224. A.J. Baillie, G.H. Coombs, T.F. Dolan, and J. Laurie Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate J. Pharm. Pharmacol. 38 1986 502 505
225. A.C. Sharon, and D.L. Wise Development of drug delivery systems for use in treatment of narcotic addiction NIDA Res. Monogr. 28 1981 194 213
226. X. Gao, and L. Huang Potentiation of cationic liposome-mediated gene delivery by polycations Biochemistry 35 1996 1027 1036
227. G.H. Lowell, W.R. Ballou, L.F. Smith, R.A. Wirtz, W.D. Zollinger, and W.T. Hockmeyer Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides Science 240 1988 800 802
228. N. Wang, and X.S. Wu Preparation and characterization of agarose hydrogel nanoparticles for protein and peptide drug delivery Pharm. Dev. Technol. 2 1997 135 142
229. J. Kost, and S. Shefer Chemically-modified polysaccharides for enzymatically-controlled oral drug delivery Biomaterials 11 1990 695 698
230. A.J. Currie, G.A. Stewart, and A.S. McWilliam Alveolar macrophages bind and phagocytose allergen-containing pollen starch granules via C-type lectin and integrin receptors: implications for airway inflammatory disease J. Immunol. 164 2000 3878 3886
231. M.E. Planas, P. Gonzalez, L. Rodriguez, S. Sanchez, and G. Cevc Noninvasive percutaneous induction of topical analgesia by a new type of drug carrier, and prolongation of local pain insensitivity by anesthetic liposomes Anesth. Analg. 75 1992 615 621
232. R. Gluck, R. Mischler, S. Brantschen, M. Just, B. Althaus, and S.J. Cryz Jr. Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A J. Clin. Invest. 90 1992 2491 2495
233. A.J. Kingsman, N.R. Burns, G.T. Layton, and S.E. Adams Yeast retrotransposon particles as antigen delivery systems Ann. N. Y. Acad. Sci. 754 1995 202 213
234. Y. Tabata, and Y. Ikada Macrophage phagocytosis of biodegradable microspheres composed of l-lactic acid/glycolic acid homo- and copolymers J. Biomed. Mater. Res. 22 1988 837 858